temafloxacin

(redirected from Omniflox)

temafloxacin

Omniflox® Antibiotics An advanced fluoroquinolone active against streptococci and anaerobes; it was withdrawn from the market. See Fluoroquinolone, Temafloxacin syndrome.
Mentioned in ?
References in periodicals archive ?
market, including Abbott Laboratories' Omniflox, an antibiotic that caused hemolytic anemia; Warner-Lambert's Rezulin, a diabetes drug that caused acute liver failure; Wyeth's Fen-Phen and Redux, weight loss drugs that caused heart valve injury; and PPA (phenyl-propanolamine), an over-the-counter decongestant and weight loss product that caused hemorrhagic stroke in young women.
Its attorneys had lead counsel roles in mass tort litigation since the early 1970's including DES, Dalkon Shield, Toxic Shock Syndrome, Flight 255 MDL (multi district litigation), Korean Airlines, Omniflox MDL, and breast implant litigations.
Dickinson as a result of taking the prescription antibiotic Omniflox.
Omniflox (Temafloxacin Hydochloride), a synthetic quinolone antibiotic, was manufactured, marketed, distributed and sold by Abbott Laboratories during a three month period in 1992.
Omniflox was approved by the Food and Drug Administration (FDA) on January 30, 1992.
The deaths and injuries caused by Omniflox resulted from and included kidney failure, liver failure, the breakdown of red blood cells, the abnormal accumulation of fluid in the lungs, internal bleeding at multiple sites, significant drops in blood pressure and vascular collapse.
Omniflox was one of a new class of antibiotics based on a quinine structured pharmaceutical and was used to treat respiratory, skin, prostate and urinary tract infections.
introduction of Omniflox (temafloxacin), an Abbott-discovered quinolone anti-infective.
31 /PRNewswire/ -- Abbott Laboratories (NYSE: ABT) announced today that Omniflox (temafloxacin), a new quinolone antibiotic to treat certain lower respiratory tract infections, genitourinary infections and skin infections, has cleared FDA review.
Omniflox is indicated for the treatment of lower respiratory tract infections (pneumonia, bronchitis), genitourinary infections (prostatitis, urinary tract infection) and skin infections.
Omniflox, discovered and developed by Abbott scientists, is the second new antibiotic introduced in the U.
With Biaxin and Omniflox, we are well- positioned to compete successfully in this marketplace during the 1990s.